Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
benmelstobart + anlotinib + platinum + etoposide
- Development stage
- Phase 2
- Lead developer
- Sino Biopharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This investigational combination therapy is being evaluated as a first-line treatment for advanced large-cell neuroendocrine carcinoma (LCNEC) and extrapulmonary neuroendocrine carcinoma (EP-NEC). The regimen consists of benmelstobart, a humanized IgG1 monoclonal antibody targeting PD-L1; anlotinib, a multi-targeted small molecule tyrosine kinase inhibitor; and a chemotherapy backbone of etoposide plus a platinum agent (cisplatin or carboplatin). Benmelstobart functions as an immune checkpoint inhibitor by blocking the PD-1/PD-L1 pathway, while anlotinib inhibits angiogenesis and tumor proliferation by targeting VEGFR, FGFR, PDGFR, and c-Kit. The addition of cytotoxic chemotherapy (platinum and etoposide) provides a synergistic effect by inducing DNA damage and inhibiting topoisomerase II. This specific combination is currently being investigated in a Phase II clinical trial led by Tianjin Medical University Cancer Institute and Hospital.
- Other names
- Benmelstobart + Anlotinib + Chemotherapy
02
Targets
CD80 (T-lymphocyte activation antigen CD80)DNATOP2A (DNA topoisomerase II)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on benmelstobart + anlotinib + platinum + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on benmelstobart + anlotinib + platinum + etoposide.